The Fixed-dose Combination of Losartan/hydrochlorothiazide Elicits Potent Blood Pressure Lowering During Nighttime in Obese Hypertensive Patients

Overview

Journal J Clin Med Res

Specialty General Medicine

Date 2014 Jan 9

PMID 24400025

Citations 1

Authors

Chikao Ibuki

Yoshihiko Seino

Toshiaki Otsuka

Kyoichi Mizuno

Affiliations

Soon will be listed here.

Abstract

Background: Hypertension is one of the most powerful predictor of the future cardiovascular events, and antihypertensive therapy adopting multiple drug regimen is often needed to obtain the appropriate blood pressure (BP) control. To clarify the blood pressure-lowering effect of the fixed-dose combination (FDC) of an angiotensin receptor blocker (ARB) and diuretic agent in poorly controlled hypertensive patients, we intended a multicenter prospective observational study (Investigation for Normalized Blood pressure control with the Appropriate medication: INBA) by means of the sequential ambulatory blood pressure monitoring (ABPM).

Methods: One hundred and thirteen hypertensive patients who had not achieved the target BP control proposed in the guidelines with medication containing any ARB but without diuretic agents (54 men; mean age, 66 years old; mean office systolic/diastolic BP (SBP/DBP), 158/82 mmHg) were enrolled. Daytime and nighttime blood pressures were assessed with ABPM before and at 12 weeks after switching the ARB to the FDC of 50 mg of losartan, and 12.5 mg of hydrochlorothiazide (HCTZ).

Results: Daytime SBP/DBP (mean ± SD) decreased from 151 ± 14/88 ± 8 mmHg to 140 ± 11/82 ± 8 mmHg (P < 0.001, P < 0.001, respectively), and nocturnal SBP/DBP from 138 ± 18/78 ± 9 mmHg to 125 ± 14/72 ± 9 mmHg (P < 0.001, P < 0.001, respectively) during the 12 weeks treatment. Pulse rate did not change irrespective of the time window. Among various parameters (age, history of hypertension, body mass index (BMI), serum potassium, uric acid, estimated glomerular filtration rate, plasma B-type natriuretic peptide), BMI alone showed significant negative correlation with 12-weeks reduction in nocturnal SBP (r = -0.43, P < 0.05). No parameters correlated with reduction in daytime SBP during this period. Patients with BMI ≥ median (25.8 kg/m(2)) showed significantly greater reduction in nocturnal SBP for 12 weeks than patients with BMI < median (20.1 ± 15.6 mmHg vs 6.1 ± 10.9 mmHg, P < 0.001) although reduction in daytime SBP was comparable between the two groups (8.9 ± 13.5 mmHg vs 11.9 ± 12.7 mmHg).

Conclusions: The administration of the FDC of losartan/HCTZ lowers BP both in day- and nighttime, and the nocturnal antihypertensive potency is remarkable in obese patients.

Citing Articles

Lercanidipine/enalapril combination in the management of obesity-related hypertension.

Grassi G Integr Blood Press Control. 2016; 9:69-77.

PMID: 27175094 PMC: 4854233. DOI: 10.2147/IBPC.S92779.

References

Uzu T, Sakaguchi M, Yokomaku Y, Kume S, Kanasaki M, Isshiki K . Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. Clin Exp Nephrol. 2009; 13(4):300-306. DOI: 10.1007/s10157-009-0157-7. View

Bianchi S, Bigazzi R, Baldari G, Sgherri G, Campese V . Diurnal variations of blood pressure and microalbuminuria in essential hypertension. Am J Hypertens. 1994; 7(1):23-9. DOI: 10.1093/ajh/7.1.23. View

. Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2004). Hypertens Res. 2007; 29 Suppl:S1-105. DOI: 10.1291/hypres.29.s1. View

Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J . Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension. 2001; 38(6):E28-32. DOI: 10.1161/hy1101.099502. View

Lida M, Ueda K, Okayama A, Kodama K, Sawai K, Shibata S . Impact of elevated blood pressure on mortality from all causes, cardiovascular diseases, heart disease and stroke among Japanese: 14 year follow-up of randomly selected population from Japanese -- Nippon data 80. J Hum Hypertens. 2004; 17(12):851-7. DOI: 10.1038/sj.jhh.1001602. View

Dahlof B, Devereux R, Kjeldsen S, Julius S, Beevers G, de Faire U . Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359(9311):995-1003. DOI: 10.1016/S0140-6736(02)08089-3. View

. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24):3255-64. View

Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M . The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res. 2009; 32(1):3-107. View

Yano Y, Kario K . Nocturnal blood pressure and cardiovascular disease: a review of recent advances. Hypertens Res. 2012; 35(7):695-701. DOI: 10.1038/hr.2012.26. View

10.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K . Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53(6):982-92. DOI: 10.1053/j.ajkd.2008.12.034. View

11.

Jamerson K, Weber M, Bakris G, Dahlof B, Pitt B, Shi V . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359(23):2417-28. DOI: 10.1056/NEJMoa0806182. View

12.

Messerli F, Makani H, Benjo A, Romero J, Alviar C, Bangalore S . Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011; 57(5):590-600. DOI: 10.1016/j.jacc.2010.07.053. View

13.

Hansen T, Li Y, Boggia J, Thijs L, Richart T, Staessen J . Predictive role of the nighttime blood pressure. Hypertension. 2010; 57(1):3-10. DOI: 10.1161/HYPERTENSIONAHA.109.133900. View

14.

Kannel W . Framingham study insights into hypertensive risk of cardiovascular disease. Hypertens Res. 1995; 18(3):181-96. DOI: 10.1291/hypres.18.181. View

15.

Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R . Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation. Circulation. 1997; 95(6):1464-70. DOI: 10.1161/01.cir.95.6.1464. View

16.

Staessen J, Thijs L, Fagard R, OBrien E, Clement D, de Leeuw P . Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial Investigators. JAMA. 1999; 282(6):539-46. DOI: 10.1001/jama.282.6.539. View

17.

Verdecchia P, Schillaci G, Guerrieri M, GATTESCHI C, Benemio G, Boldrini F . Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation. 1990; 81(2):528-36. DOI: 10.1161/01.cir.81.2.528. View

18.

Franse L, Pahor M, Di Bari M, Somes G, Cushman W, Applegate W . Hypokalemia associated with diuretic use and cardiovascular events in the Systolic Hypertension in the Elderly Program. Hypertension. 2000; 35(5):1025-30. DOI: 10.1161/01.hyp.35.5.1025. View

19.

Schillaci G, Verdecchia P, Borgioni C, Ciucci A, Guerrieri M, Zampi I . Improved electrocardiographic diagnosis of left ventricular hypertrophy. Am J Cardiol. 1994; 74(7):714-9. DOI: 10.1016/0002-9149(94)90316-6. View

20.

Minami J, Abe C, Akashiba A, Takahashi T, Kameda T, Ishimitsu T . Long-term efficacy of combination therapy with losartan and low-dose hydrochlorothiazide in patients with uncontrolled hypertension. Int Heart J. 2007; 48(2):177-86. DOI: 10.1536/ihj.48.177. View